Compare ESQ & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESQ | CRMD |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.0M | 695.9M |
| IPO Year | 2017 | 2009 |
| Metric | ESQ | CRMD |
|---|---|---|
| Price | $129.22 | $7.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $120.33 | $14.83 |
| AVG Volume (30 Days) | 137.2K | ★ 907.1K |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | 14.20 | ★ 780.00 |
| EPS | ★ 1.40 | 0.43 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | $35.15 | $0.30 |
| Revenue Next Year | $39.09 | N/A |
| P/E Ratio | $92.79 | ★ $17.44 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $91.74 | $6.13 |
| 52 Week High | $132.69 | $14.96 |
| Indicator | ESQ | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 65.17 | 38.92 |
| Support Level | $103.79 | $7.05 |
| Resistance Level | N/A | $7.44 |
| Average True Range (ATR) | 4.13 | 0.37 |
| MACD | 0.78 | -0.10 |
| Stochastic Oscillator | 87.10 | 19.99 |
Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.